Contact

Media Coverage


Nearly 50,000 people are diagnosed with oral cancer in the U.S. each year—and that number continues to grow, particularly among certain segments of the population.

More than 49,750 people in the United States will be diagnosed with oral cancer this year, according to Vigilant Biosciences. Yet 62% of adults in the US know very little or nothing at all about the disease—including cancer of the oral cavity, tongue, larynx, and pharynx—and only 29% report being screened for oral cancer at their last dental checkup.

Vigilant Biosciences’ CEO Matthew H.J. Kim offers insight surrounding the link between HPV and oral cancer.

In the United States, awareness and education surrounding oral cancer is low. In observance of National Oral Cancer Awareness Month and Oral, Head and Neck Cancer Awareness Week this April, Vigilant Biosciences joined with the Head and Neck Cancer Alliance, the Oral Cancer Foundation, and Support for People with Oral and Head and Neck Cancer to launch a campaign to raise awareness about oral cancer and its risk factors.

Vigilant Biosciences’ Scientific Co-Founder and Chief Scientific Officer Elizabeth Franzmann, M.D., recently caught up with WPLG to discuss oral cancer and the Company’s OncAlert Oral Cancer product line.

According to a recently released national survey, the majority (62 percent) of adults in the U.S. know very little, or nothing at all, about oral cancer (including cancer of the oral cavity, tongue, larynx and pharynx), and only 29 percent report being screened for oral cancer at their last dental checkup.

According to a recent survey released today from Vigilant Biosciences, in collaboration with the Oral Cancer Foundation, HNCA and SPOHNC, more than 60% of consumers know very little or nothing about oral cancer – a disease that nearly 50,000 people are diagnosed with in the US every year.

Only 29% of U.S. patients reported being screened for oral cancer at their last visit to the dental office, according to a new survey released by the Oral Cancer Foundation, the Head and Neck Cancer Alliance, Vigilant Biosciences, and Support for People with Oral and Head and Neck Cancer.

 

According to a recent survey conducted by Vigilant Biosciences in collaboration with the Oral Cancer Foundation, Head and Neck Cancer Alliance, and Support for People with Oral and Head and Neck Cancer, more than 60% of consumers know very little or nothing about oral cancer—a disease that nearly 50,000 people are diagnosed with in the United States every year.

 

The OncAlert oral cancer product line from Vigilant Biosciences Inc, Fort Lauderdale, Fla, is now available in select markets. The company’s OncAlert oral cancer product line includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting the CE mark. The tests are based on technology that accurately measures CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels—markers clinically validated to be associated specifically with oral cancer. The tests are optimized for easy use by collecting samples via an oral saline rinse, and are performed via either a point-of-care lateral-flow assay or a laboratory kit. The test results, along with other clinical factors, can aid in the early diagnosis of oral cancer, potentially even before visual or physical indicators. According to a company spokesperson, Vigilant Biosciences has plans to pursue FDA approval on the OncAlert oral cancer product line in the near future. For more information, visit Vigilant Biosciences.

The OncAlert oral cancer product line from Vigilant Biosciences Inc, Fort Lauderdale, Fla, is now available in select markets. The company’s OncAlert oral cancer product line includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting the CE mark.

For Matthew Kim, the idea for his company came when he was taking his mother to doctor visits for her cancer treatments.

She was on her third battle with oral cancer, while Kim had a consulting firm and the fortunate flexibility to take her to her chemotherapy, radiation and rehabilitation.